poisar

Stocks · News reference

VolitionRx shares are trading lower. The company announced the publication of a peer‑reviewed paper and editorial showing its Nu.Q NETs H3.1 biomarker predicts 28‑day mortality and need for renal replacement therapy in sepsis patients.

BenzingaAug 26, 2026, 4:23 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 26, 2026, 4:23 PM
Checked
Aug 26, 2026, 4:23 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading